close
close

Sublocade shows promising results in treating opioid addiction By Investing.com

RICHMOND, Va. – Indivior PLC (NASDAQ:LSE: INDV), a pharmaceutical company, has published research supporting the effectiveness and safety of its drug SUBLOCADE in the treatment of opioid addiction (OUD). Data released during Addiction Prevention Month emphasizes the importance of access to long-acting injectable treatments like SUBLOCADE for long-term recovery.

Recent studies, including a Phase 3 study published in the Harm Reduction Journal, show that the 300 mg dose of SUBLOCADE significantly increases opioid abstinence in users who inject opioids. Results from the Community Long-Acting Buprenorphine (CoLAB) study, published in the International Journal of Drug Policy, also demonstrate sustained improvements in abstinence and quality of life for up to 96 weeks.

Access to medication-assisted treatment (MOUD) remains a challenge. A study published in American Health & Drug Benefits found that telemedicine plays a key role in overcoming barriers, especially during the COVID-19 pandemic. A review in Corrections Today highlights the disparity in access to MOUD between the general population and those incarcerated, with stigma and informed consent posing significant barriers.

Dr. Christian Heidbreder, Chief Scientific Officer at Indivior, explained that the collected evidence underscores the importance of access to MOUDs such as SUBLOCADE to reduce barriers to adherence and improve recovery outcomes. Indivior is committed to advancing patient understanding, advancing evidence-based practices and overcoming stigma.

SUBLOCADE is an injectable form of buprenorphine used to treat moderate to severe OUD as part of a comprehensive treatment plan that includes counseling and psychosocial support. Due to the risks associated with intravenous administration, it is only available through a restricted program.

Despite the nearly 6 million Americans ages 12 and older with OUD in 2023, only about 18% received MOUD treatment. Individuals purposefully aim to close this treatment gap and support the recovery of people with OUD.

This article is based on a press release.

In other recent news, pharmaceutical company Indivior recorded a number of notable developments. Indivior reported third-quarter results that met revenue expectations and beat profit forecasts, prompting Piper Sandler to raise its price target on the company's shares to $16.00. Despite some weaknesses in the C&V business segment, Piper Sandler maintains an overweight rating on Indivior shares.

Indivior also revised its full-year 2024 revenue guidance for its product Sublocade due to increased competition. The company now expects revenue for Sublocade to be between $725 million and $745 million. However, Craig-Hallum believes in the company's resilience and growth potential despite lowering its individual price target from $24.00 to $20.00.

The U.S. Food and Drug Administration (FDA) has granted priority review to a Prior Approval Supplement (PAS) for Sublocade, which could potentially improve treatment options. Indivior also secured an $8.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for Opvee, an opioid overdose reversal drug. These are recent developments that investors should consider when evaluating the financial health of individuals.

InvestingPro Insights

As Indivior PLC (NASDAQ:LSE: INDV) continues to make progress in closing the opioid addiction treatment gap, investors may find it valuable to examine the company's financial health and market performance. According to InvestingPro data, Indivior's revenue growth is 13.44% for the trailing twelve months through the third quarter of 2024, consistent with the company's push to expand access to its SUBLOCADE treatment.

The company's gross margin of 82.4% for the same period indicated strong pricing power for its pharmaceutical products, which may be due to SUBLOCADE's unique positioning in the OUD treatment market. This high margin could give Indivior the financial flexibility to invest in research and development and initiatives to overcome barriers to treatment access.

InvestingPro Tips highlights that Indivior's net income is expected to grow this year, which could be a positive sign for its investors considering the company's focus on expanding its treatment offerings. Additionally, analysts predict the company will be profitable this year, perhaps reflecting the market's confidence in Indivior's business model and growth strategy.

It is worth noting that InvestingPro offers 11 additional tips for Indivior that provide a more comprehensive analysis for investors interested in the company's prospects. These insights could be particularly valuable given the company's position in the evolving OUD treatment landscape.

This translation was created using artificial intelligence. For further information, please see our Terms of Use.